Comparative Pharmacology
Head-to-head clinical analysis: PHENERGAN VC versus TAVIST 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENERGAN VC versus TAVIST 1.
PHENERGAN VC vs TAVIST-1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenergan VC is a combination of promethazine (a phenothiazine derivative with antihistaminic, sedative, antiemetic, and anticholinergic effects) and phenylephrine (a sympathomimetic amine that acts as a decongestant via alpha-1 adrenergic receptor agonism). Promethazine antagonizes H1 receptors, thereby suppressing allergic reactions and motion sickness. Phenylephrine causes vasoconstriction in the nasal mucosa, reducing congestion.
TAVIST-1 (clemastine fumarate) is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors, thereby preventing histamine-mediated effects such as vasodilation, increased capillary permeability, and bronchoconstriction. It also exhibits anticholinergic and sedative properties.
10-20 mL orally every 4-6 hours as needed; each 5 mL contains 6.25 mg promethazine HCl and 5 mg phenylephrine HCl.
1.34 mg orally twice daily; maximum 8.04 mg/day.
None Documented
None Documented
9-16 hours; prolonged in hepatic impairment.
Terminal half-life 12–15 hours; clinical dosing interval every 12 hours.
Renal: 70-80% as metabolites; biliary/fecal: 20-30%.
Primarily renal: ~60% unchanged; biliary/fecal: ~30% as metabolites; minor via feces.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine